Grant Avenue Capital has launched a new clinical trial-focused portfolio company through the roll-up of 20 smaller trial sites, the latest example of a PE firm capitalizing on a hyper-fragmented market segment.
Roll-ups are a tried-and-true strategy for PE firms seeking to profit off of industries made up of small or inefficient companies. Firms in other healthcare categories—namely dental, dermatology, vision, veterinary and surgical—have long been conducting buy-and-build plays. Since 2020, Southern Veterinary Partners, a key player in acquisitions of animal hospitals, has conducted 113 add-ons, making it the most acquisitive PE-backed healthcare service platform in the same time frame, according to PitchBook’s Q3 2022 Healthcare Services Report.
Roll-ups are the bread and butter of the healthcare investing space, said Rebecca Springer, senior healthcare analyst at PitchBook. These types of transactions are particularly important in the clinical trial space, which lacks technological advancements and is notoriously bogged down with administrative work.
“Often data for the [clinical] trial is being collected on paper and then transcribed into two different systems,” Springer said. “It’s a very inefficient process.”
Now, Grant Avenue, which focuses on the middle market, has announced the launch of Helios Clinical Research, a clinical site organization that recruits patients and principal investigators for clinical trials, gathers trial data, and manages regulatory and quality compliance.
The firm, which defines its middle-market target as between $5 million and $25 million in EBITDA, acquired and partnered with 20 clinical research sites, which it then rolled up to create Helios—a familiar strategy for PE firms. The 20 companies that became Helios focus on a range of research areas including vaccines, metabolic, urology, orthopedics, gastroenterology, dermatology, oncology and general medicine.
Preston Brice, a partner at Grant Avenue who led the Helios transaction, said the roll-up was a result of “hyper-fragmentation” in the market segment.
“In fact, the top 10 largest players in the space only make up about 11% market share,” Brice said.
Grant Avenue hopes to grow Helios organically and through additional acquisitions and partnerships.
The Helios transaction is also a result of a microtrend in the healthcare sector: an increased demand for outsourced or “customized” services from third-party vendors, like Helios, that provide services to bigger players like pharmaceutical companies and hospitals.
According to Brice and Buddy Gumina, founder of Grant Avenue, inflation-driven rising costs for healthcare providers and heightened regulatory requirements have increased the demand for third-party services.
"[Outsourced companies] are going to do it better, faster and more cost effectively with a higher-quality outcome,” Brice said.
Update: This story has been updated to reflect that Helios Clinical Research is a clinical site organization. (Nov. 17, 2022)
Featured image by Sai Thaw Kyar/Shutterstock
Learn about our editorial standards.